FARICIMAB\FARICIMAB-SVOA: 3,312 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

3,312

Total FAERS Reports

97 (2.9%)

Deaths Reported

Hospitalizations

3,312

As Primary/Secondary Suspect

Life-Threatening

Disabilities

First Report: 20050101 · Latest Report: 20240917

What Are the Most Common FARICIMAB\FARICIMAB-SVOA Side Effects?

#1 Most Reported

No adverse event

1,553 reports (46.9%)

#2 Most Reported

Off label use

1,550 reports (46.8%)

#3 Most Reported

Visual impairment

208 reports (6.3%)

Side Effect	Reports	% of Total	Deaths	Hosp.
No adverse event	1,553	46.9%	0	0
Off label use	1,550	46.8%	5	7
Visual impairment	208	6.3%	1	10
Drug ineffective	176	5.3%	0	2
Uveitis	153	4.6%	0	6
Eye inflammation	124	3.7%	0	4
Vitreous floaters	123	3.7%	0	4
Vision blurred	99	3.0%	0	1
Vitritis	99	3.0%	0	8
Endophthalmitis	93	2.8%	0	11
Iridocyclitis	91	2.8%	0	6
Death	85	2.6%	83	0
Intraocular pressure increased	70	2.1%	0	0
Visual acuity reduced	70	2.1%	0	2
Eye pain	69	2.1%	1	1
Blindness	64	1.9%	1	3
Intercepted product storage error	54	1.6%	0	0
Eye disorder	49	1.5%	0	0
Retinal haemorrhage	39	1.2%	0	4
Pain	38	1.2%	1	1

Gender: 50.8% female, 49.2% male. Average age: 69.1 years. Most reports from: US. View detailed demographics →

Year	Reports	Deaths	Hosp.
2005	1	0	1
2009	1	0	0
2010	1	0	0
2012	1	0	0
2015	2	0	0
2018	2	0	0
2021	3	0	0
2022	30	6	2
2023	278	32	19
2024	603	26	33

Indication	Reports
Neovascular age-related macular degeneration	1,019
Product used for unknown indication	683
Diabetic retinal oedema	434
Choroidal neovascularisation	306
Macular oedema	249
Diabetic retinopathy	233
Retinal vein occlusion	189
Age-related macular degeneration	185
Retinal neovascularisation	149
Macular degeneration	111

Official prescribing information from the FDA-approved drug label.